laboratory specialized in the treatment of rare neurological diseases
  • [Corporate] Home Banner

About Theranexus

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.

Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

Theranexus announces first half 2024 financial results

26/09/2024 18:00
Download PDF File (<1 Mo)

Theranexus, Diverchim and Inserm awarded €4.7 million in funding under the “Innovations in biotherapies and biomanufacturing” call for proposals from France 2030 to develop a novel antisense oligonucleotide

23/04/2024 07h30
Télécharger le PDF (<1Mo)

Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1

18/04/2024 18h00
Télécharger le PDF (<1Mo)

Theranexus announces appointment of Mathieu Charvériat as Board of Directors Chairman 

11/03/2024 8am CET
Download PDF File (<1 Mo)

Theranexus publishes its cash position as of December 31st 2023 and presents an update on its programs 

14/02/2024
Download PDF File (<1 Mo)